Cencora, Inc. (NYSE:COR) Shares Bought by Czech National Bank

Czech National Bank increased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 4.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,640 shares of the company's stock after buying an additional 1,615 shares during the quarter. Czech National Bank's holdings in Cencora were worth $11,023,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in COR. Hickory Asset Management Inc. acquired a new stake in Cencora in the 4th quarter worth approximately $572,000. Sylvest Advisors LLC acquired a new stake in Cencora during the 4th quarter valued at approximately $1,105,000. Vontobel Holding Ltd. boosted its holdings in shares of Cencora by 46.9% in the 4th quarter. Vontobel Holding Ltd. now owns 6,245 shares of the company's stock valued at $1,403,000 after acquiring an additional 1,995 shares during the last quarter. Portfolio Design Labs LLC increased its stake in shares of Cencora by 76.9% in the fourth quarter. Portfolio Design Labs LLC now owns 11,032 shares of the company's stock worth $2,479,000 after acquiring an additional 4,794 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its holdings in shares of Cencora by 4.4% during the fourth quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 28,575 shares of the company's stock worth $6,420,000 after purchasing an additional 1,200 shares during the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Trading Down 0.0%

COR traded down $0.14 on Thursday, hitting $288.89. The company had a trading volume of 212,230 shares, compared to its average volume of 1,527,679. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm has a market cap of $55.99 billion, a P/E ratio of 41.09, a PEG ratio of 1.31 and a beta of 0.60. The company's fifty day moving average price is $285.86 and its 200 day moving average price is $259.51. Cencora, Inc. has a 1 year low of $218.65 and a 1 year high of $309.35.

Cencora (NYSE:COR - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The business had revenue of $75.50 billion for the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The business's revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $3.80 EPS. As a group, equities analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a $0.55 dividend. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. Cencora's payout ratio is presently 25.52%.

Analyst Upgrades and Downgrades

COR has been the subject of several recent research reports. Citigroup lifted their price target on Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Robert W. Baird raised their price objective on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Wall Street Zen raised shares of Cencora from a "hold" rating to a "buy" rating in a report on Wednesday, March 12th. Morgan Stanley set a $288.00 price target on shares of Cencora in a report on Tuesday, April 15th. Finally, Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $274.00 to $337.00 in a research report on Tuesday. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $306.91.

Insider Activity at Cencora

In other news, EVP Elizabeth S. Campbell sold 4,127 shares of the company's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $268.28, for a total transaction of $1,107,191.56. Following the completion of the transaction, the executive vice president now directly owns 14,665 shares of the company's stock, valued at approximately $3,934,326.20. This represents a 21.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Chairman Steven H. Collis sold 14,579 shares of the business's stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the sale, the chairman now owns 315,913 shares of the company's stock, valued at approximately $89,027,442.53. The trade was a 4.41% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 40,253 shares of company stock worth $11,102,417. 10.80% of the stock is currently owned by company insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.